TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03607578

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Protection Routine 1
Description: New folder, sun advice of Danish Sun Safety Campaign, rationale, prioritization, overview of sun prevention. Activity planner with outdoor activities like bathing, sports and excursions before and after noon (UVI maximum) and indoor activities; shopping, lunch, relaxation and transportation in middle of day and possibility to plan vacation to minimize risk. Instructions for download of UV-App includes use of alert, and information about the features of the app; how to be informed of current UV risk before and during vacation. Link for download of the app is sent by text-message and e-mail. Skintype guide is included in the app and as an individual entity. It includes scoring questions about tan and burn reaction in the sun, a color scale, eye and hair color and freckles. Participants get a description of their skin type and examples of time their particular skin type will resist the sun before erythema occurs at particular UV-levels and functions as an eye-opener.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Protection Routine 2
Description: The sunscreen application instruction is based on a recently developed thorough application instructions for use of sunscreen to counter the problems and deficits of current sunscreen use. It describes every part of the body, the needed volume for that part and application patterns. The package will also include a hat specifically designed for protection and comfort and the availability of a hat will function to increase the use of hat. The hat is simple bucket hat version with a brim, cheap, in light fabric and foldable for easy packing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Protection Routine 2
Description: The sunscreen application instruction is based on a recently developed thorough application instructions for use of sunscreen to counter the problems and deficits of current sunscreen use. It describes every part of the body, the needed volume for that part and application patterns. The package will also include a hat specifically designed for protection and comfort and the availability of a hat will function to increase the use of hat. The hat is simple bucket hat version with a brim, cheap, in light fabric and foldable for easy packing.
Study: NCT00754533

Intervention type: OTHER
Group type: OTHER
Intervention: Continuous versus interval training
Description: Influence of different exercise training programs

Intervention type: OTHER
Group type: OTHER
Intervention: Continuous versus interval training
Description: Influence of different exercise training programs
Study: NCT01182285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Week 1:~(Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening
Study: NCT00226941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine hydrochloride (HCl)
Description: Diphenhydramine HCl 50 mg (or equivalent) is administered as a per-medication for cetuximab
Study: NCT00849342

Intervention type: DRUG
Intervention: insulin detemir
Description: Safety and effectiveness (weight and HbA1c) data collection in connection with the use of the drug Levemir® in daily clinical practice.
Study: NCT05423509

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic myofascial manipulation
Description: Dynamic myofascial manipulation of the muscles in the back to improve the scoliosis appearance/flexibility/rotation

Intervention type: OTHER
Group type: OTHER
Intervention: Standard AIS treatment with observation or bracing
Description: Observation with radiographs and bracing of curves greater than 20 degrees

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard AIS treatment with observation or bracing
Description: Observation with radiographs and bracing of curves greater than 20 degrees
Study: NCT04204421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experience Sampling Method (ESM)
Description: Experience Sampling Method (ESM) is a method for real time complaints assessment where people are asked to fill out a questionnaire 10 times per day at random moments. This will be done via a mobile phone application.
Study: NCT01172938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 20mg
Description: Apremilast 20 mg twice daily, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 30mg
Description: Apremilast 30 mg twice daily, orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + 20 mg Apremilast
Description: Placebo + 20 mg Apremilast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + 30 mg Apremilast
Description: Placebo + 30 mg Apremilast
Study: NCT00917345

Intervention type: DRUG
Intervention: captopril test
Description: The blood samplings were obtained one hour after the administration of 50 mg of captopril.The testing is performed in the morning on a seated ambulatory patient

Intervention type: DRUG
Intervention: captopril test
Description: The blood samplings were obtained one hour after the administration of 50 mg of captopril.The testing is performed in the morning on a seated ambulatory patient
Study: NCT01332305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn (XP13512/GSK1838262)
Description: Double-Blind Treatment Phase: 600 mg GEn (XP13512) orally, once daily for 3 days followed by 600 or 1200 mg on days 4-6, followed by 600 or 1200 or 1800 mg on days 7-9, followed by 600 or 1200 or 1800 or 2400 mg on days 10-84. Double-Blind Taper Phase: 600 or 1200 or 1800 mg GEn (XP13512) orally, once daily on days 85-86, followed by 600 mg or 1200 mg on days 87-88, followed by 600 mg on days 89-91

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn (XP13512/GSK1838262)
Description: Double-Blind Treatment Phase: 600 mg GEn (XP13512) orally, once daily for 3 days followed by 600 or 1200 mg on days 4-6, followed by 600 or 1200 or 1800 mg on days 7-9, followed by 600 or 1200 or 1800 or 2400 mg on days 10-84. Double-Blind Taper Phase: 600 or 1200 or 1800 mg GEn (XP13512) orally, once daily on days 85-86, followed by 600 mg or 1200 mg on days 87-88, followed by 600 mg on days 89-91

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn (XP13512/GSK1838262)
Description: Double-Blind Treatment Phase: 600 mg GEn (XP13512) orally, once daily for 3 days followed by 600 or 1200 mg on days 4-6, followed by 600 or 1200 or 1800 mg on days 7-9, followed by 600 or 1200 or 1800 or 2400 mg on days 10-84. Double-Blind Taper Phase: 600 or 1200 or 1800 mg GEn (XP13512) orally, once daily on days 85-86, followed by 600 mg or 1200 mg on days 87-88, followed by 600 mg on days 89-91

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn (XP13512/GSK1838262)
Description: Double-Blind Treatment Phase: 600 mg GEn (XP13512) orally, once daily for 3 days followed by 600 or 1200 mg on days 4-6, followed by 600 or 1200 or 1800 mg on days 7-9, followed by 600 or 1200 or 1800 or 2400 mg on days 10-84. Double-Blind Taper Phase: 600 or 1200 or 1800 mg GEn (XP13512) orally, once daily on days 85-86, followed by 600 mg or 1200 mg on days 87-88, followed by 600 mg on days 89-91

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally once daily
Study: NCT01554046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate- Ritalin IR (Immediate Release)
Description: Duration of treatment- 4 weeks. Dosage- up to 3 times/day.~* Ages 6-12, up to 25Kg - 35mg maximum per day.~* Ages 6-12, above 25Kg - 50mg maximum per day.~* Ages 12-65, above 25Kg - 80mg maximum per day.
Study: NCT01931839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor Plus Ivacaftor Combination
Description: Fixed dose combination tablet, oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor Plus Ivacaftor Combination
Description: Fixed dose combination tablet, oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor Plus Ivacaftor Combination
Description: Fixed dose combination tablet, oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor Plus Ivacaftor Combination
Description: Fixed dose combination tablet, oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor Plus Ivacaftor Combination
Description: Fixed dose combination tablet, oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor Plus Ivacaftor Combination
Description: Fixed dose combination tablet, oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: Film-coated tablet, oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: Film-coated tablet, oral use
Study: NCT05826821

Intervention type: DRUG
Intervention: Pirfenidone
Description: Intervention drug
Study: NCT01992536

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY+OMV
Description: Vaccine contains rMenB (50 µg per antigen) with 25 µg of OMV (a full dose) plus the fully lyophilized MenACWY vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY+OMV
Description: Vaccine contains rMenB (50 µg per antigen) with 25 µg of OMV (a full dose) plus the fully lyophilized MenACWY vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY+OMV
Description: Vaccine contains rMenB (50 µg per antigen) with 25 µg of OMV (a full dose) plus the fully lyophilized MenACWY vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY+¼OMV
Description: Vaccine contains rMenB (50 µg per antigen) with 6.25 µg OMV (1/4 dose) plus the fully lyophilized MenACWY vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY+¼OMV
Description: Vaccine contains rMenB (50 µg per antigen) with 6.25 µg OMV (1/4 dose) plus the fully lyophilized MenACWY vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY+¼OMV
Description: Vaccine contains rMenB (50 µg per antigen) with 6.25 µg OMV (1/4 dose) plus the fully lyophilized MenACWY vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution for injection (0.5mL)
Study: NCT01182285

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproic Acid
Description: Week 1:~(Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproic Acid
Description: Week 1:~(Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liothyronine Sodium
Description: Patients who exhibit an increased radioiodine uptake on Thyrogen scan post valproic acid therapy at week 10. Begin Cytomel for 4 weeks (25 micrograms twice a day)
Study: NCT00841321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo biloba
Description: 120 mg orally twice a day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule orally twice a day for 12 weeks
Study: NCT01562288

Intervention type: GENETIC
Intervention: DNA analysis

Intervention type: GENETIC
Intervention: gene expression analysis

Intervention type: GENETIC
Intervention: polymerase chain reaction

Intervention type: OTHER
Intervention: enzyme-linked immunosorbent assay

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study: NCT01992536

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution for injection (0.5mL)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution for injection (0.5mL)
Study: NCT03398161

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo ultra low dose radiation therapy
Study: NCT00248794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation Therapy (CRT) + Skill Training (SDG)
Description: CRT is a one on one cognitive skills training and Skill training is a group intervention to develop concrete skills of daily living.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Computer Based Cognitive Rehabilitation (ICBCR) and Skills Training (SDG)
Description: ICBCR is a computerized cognitive skills training program and Skill training is a group intervention to develop concrete skills of daily living.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills Group (SDG)
Description: Skill training is a group intervention to develop concrete skills of daily living. This is augmented with the opportunity to receive up to 5 hours of individual staff contact.
Study: NCT02632747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin will be taken once daily
Study: NCT01717235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole hydrochloride CR Tablets 2mg
Description: Ropinirole is an orally administered non-ergoline dopamine agonist. Ropinirole is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole hydrochloride CR Tablets 2mg
Description: Ropinirole is an orally administered non-ergoline dopamine agonist. Ropinirole is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
Study: NCT03512340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRF231
Description: SRF231 specifically blocks the interaction between CD47 and signal regulatory protein alpha and acts as a potent enhancer of human tumor cell phagocytosis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRF231
Description: SRF231 specifically blocks the interaction between CD47 and signal regulatory protein alpha and acts as a potent enhancer of human tumor cell phagocytosis.
Study: NCT00979238

Intervention type: GENETIC
Group type: OTHER
Intervention: Gene Transfer
Description: Peripheral vein infusion of scAAV2/8-LP1-hFIXco vector once per participant

Intervention type: DRUG
Group type: OTHER
Intervention: scAAV2/8-LP1-hFIXco
Description: Peripheral vein infusion of scAAV2/8-LP1-hFIXco vector once per participant.
Study: NCT03603405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADV/HSV-tk (gene therapy)
Description: The investigational adenovirus gene therapy injected at tumor site followed by valacyclovir, radiotherapy, and chemotherapy
Study: NCT01398449

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Elective nodal irradiation (ENI)
Study: NCT02804919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fisher & Paykel Healthcare CPAP Device
Description: Fisher \& Paykel Healthcare CPAP Device
Study: NCT03032120

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Orange juice
Description: Lean and obese subjects drank one single dose (5 mL/kg body weight) of fresh-squeezed orange juice (FOJ) and processed orange juice (POJ) followed by an ad libitum breakfast. A washout period of seven days among each beverage (FOJ, POJ and control) was applied.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Orange juice
Description: Lean and obese subjects drank one single dose (5 mL/kg body weight) of fresh-squeezed orange juice (FOJ) and processed orange juice (POJ) followed by an ad libitum breakfast. A washout period of seven days among each beverage (FOJ, POJ and control) was applied.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: Lean and obese subjects drank one single dose (5 mL/kg body weight) of an energy and sugars-matched orange-flavored drink (control), followed by an ad libitum breakfast. A washout period of seven days among each beverage (FOJ, POJ and control) was applied.
Study: NCT01398449

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant chemotherapy only
Study: NCT05045521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plyometric warm up group
Description: participants will be asked to do 10 minutes self-paced jog on motorized treadmill.~During the plyometric intervention, subjects will perform the 2 \* 8 squat jumps, 2 \* 8 scissor jumps, and 2 \* 8 double leg bounds (2 sets of 8 repetitions) as a part of warm-up, and will have 60 s to recover between each set. Prior to the intervention, participants will be shown the technique to be used during jumping through use of three videos.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance warm up
Description: participants will be asked to do 10 minutes self-paced jog on motorized treadmill.~After the jog participants will perform the 6\*10s strides with the 15% of the weight. Velocity of the strides will be controlled by the participants.~Warmup will be followed by the 10minutes rest

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control warm up group
Description: participants will be asked to do 10 minutes self-paced jog on a motorized treadmill.~After the jog participants will perform the 6\*10s strides without the weight. Velocity of the strides will be controlled by the participants. Warmup will be followed by the 10minutes rest The total amount of time spended in each of the three warm-up protocols will be recorded. Participants will be instructed to wear the same pair of running shoes during the three tests.
Study: NCT02063789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human immunoglobulin intravenous
Description: After GC5107A Intravenous injection, evaluate platelet increase
Study: NCT01168050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib 400 mg twice per day
Study: NCT03659552

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIVE Catheter
Description: Placement of a temporary LIVE Catheter central venous pacing device in the left jugular vein to pace the phrenic nerves and allow recruitment of the diaphragm muscle.
Study: NCT02114892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Resveratrol capsules of 500 mg three times per day before meals with a total dosis of 1500 mg per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Calcined magnesia capsules, 500 mg, three times per day before meals with a total dose per day of 1500 mg
Study: NCT01392352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: 2 x 400mg pazopanib tablets taken once daily for 12 weeks
Study: NCT03127943

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Efficacy for mandibular molar and canine anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Efficacy for mandibular molar and canine anesthesia
Study: NCT02855788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel 60mg/m2, Oxaliplatin 50mg/m2, Leucovorin 20mg/m2, and 5-FU 425mg/m2 IV weekly
Description: metronomic chemotherapy
Study: NCT02632747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin will be taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (matching empagliflozin)
Description: Placebo will be taken once daily
Study: NCT01018342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg
Study: NCT02546752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: THEO
Description: THEO is interactive patient engagement software that runs on an iPad tablet platform (developed by Noble.MD). THEO is the intervention in this study.
Study: NCT01018342

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macrobid® Capsules 100 mg
Study: NCT04192786

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard physiotherapy program+50 Hz local vibration
Description: Standard physiotherapy program (strength, balance, gait exercises) for 50 minutes and local vibration applied to gastrocnemius (50 Hz) for 10 minutes will be performed 3 days a week for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard physiotherapy program+100 Hz local vibration
Description: Standard physiotherapy program (strength, balance, gait exercises) for 50 minutes and local vibration applied to gastrocnemius (100 Hz) for 10 minutes will be performed 3 days a week for 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physiotherapy program
Description: Standard physiotherapy program (strength, balance, gait exercises) for 60 minutes will be performed 3 days a week for 8 weeks.
Study: NCT00753909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin (IV) 3 AUC on day 1 and day 15 every 4 weeks for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (IV) 10 mg/kg on day 1 and day 15 every 4 weeks for 6 cycles Followed by Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression
Study: NCT04098627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laughter Therapy
Description: Once weekly 30-minute long group laughter therapy session for 8 weeks
Study: NCT00753909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel (IV) 140 mg/m2,on day 1 and day 15 every 4 weeks for 6 cycles
Study: NCT01988493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib 300 mg
Description: Participants received Tepotinib 300 milligram (mg) orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib 500 mg
Description: Participants received Tepotinib 500 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib 1000 mg
Description: Participants received Tepotinib 1000 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Participants randomized to receive Tepotinib recommended Phase 2 dose (RP2D) determined from Phase 1b over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.